<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419143</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-675</org_study_id>
    <nct_id>NCT03419143</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants</brief_title>
  <acronym>ALTEA</acronym>
  <official_title>Abatacept - Long-Term Real-Life Experience in Psoriatic Arthritis (PsA) in Germany: an Observational Study (ALTEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a
      chronic inflammatory disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity index for PSoriatic Arthritis (DAPSA)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant retention rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of concomitant treatment given</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial dosage of Abatacept given</measure>
    <time_frame>At Treatment Initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Abatacept administration</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Analysis: Reasons for Abatacept initiation</measure>
    <time_frame>up to 2 years prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients previously receiving by type of Disease modifying anti-rheumatic drug (DMARD)</measure>
    <time_frame>up to 2 years prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Analysis: Socio-Demographics at Treatment Initiation</measure>
    <time_frame>At Treatment Initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Analysis: Disease history at Treatment initiation</measure>
    <time_frame>Prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Risk factors and Comorbidities</measure>
    <time_frame>At Treatment Initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Analysis: Baseline Characteristics</measure>
    <time_frame>up to 2 years prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Analysis: Change in participant characteristics and symptoms</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Rheumatologist: Geography</measure>
    <time_frame>up to 2 months prior to treatment to 12 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Rheumatologist: Type of Institution</measure>
    <time_frame>up to 2 months prior to treatment to 12 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion and type of treatment after abatacept discontinuation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of reasons for abatacept discontinuation and initiation of new therapy</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psoriatic Arthritis (PsA)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>&quot;naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population targeted by the study consists of patients with PsA that initiate
        treatment with abatacept
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age at enrollment

          -  Patients who signed an informed consent

          -  Patients diagnosed with PsA as per the criteria of the Classification of Psoriatic
             Arthritis (CASPAR) Study Group17

          -  Patients naïve of abatacept and who at their physician's discretion initiate abatacept

          -  Patients meeting criteria for abatacept treatment for PsA as specified in the German
             label

        Exclusion Criteria:

          -  Patients who are currently included in any interventional clinical trial in
             PsA/Rheumatoid Arthritis (RA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites. directly. If there is no contact information</last_name>
    <phone>please email</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nurnberg</city>
        <zip>90429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

